Risk Management Alignment for TGA-Regulated Medical Devices

ISO 13485 is the quality management system standard for medical device organizations, covering processes such as document control, design controls, CAPA, supplier management, and post-market activities. ISO 14971 is specifically focused on risk management for medical devices. In practice, ISO 13485 defines the broader quality framework, while ISO 14971 governs how hazards, risks, controls, and residual risks are identified, evaluated, and maintained throughout the device lifecycle.

The five core steps of medical device risk management are typically: risk analysis, risk evaluation, risk control, evaluation of overall residual risk acceptability, and production/post-production monitoring. For TGA-regulated devices, these steps should not remain theoretical. They need to be documented clearly and linked to Essential Principles evidence, labeling, clinical support, and post-market feedback so the file is usable during ARTG review.

TGA expects manufacturers to show that safety and performance have been systematically addressed through a risk management process consistent with ISO 14971. Just having a risk file is not enough. The file must support Essential Principles compliance and be cross-referenced within technical documentation, labeling, and clinical evidence. Alignment reduces review friction and helps demonstrate that the submission is internally consistent and defensible.

A typical review includes the risk management plan, hazard analyses, FMEAs or equivalent analyses, risk control records, residual risk evaluations, benefit-risk determinations, verification evidence, labeling, IFUs, clinical summaries, and Essential Principles documentation. The goal is to confirm that risk outputs are current, traceable, and consistently reflected across the broader ARTG submission package rather than sitting in isolation.

Yes. In many cases, the most efficient approach is to review and adapt an existing ISO 14971-compliant file rather than rebuild it from scratch. Elexes identifies where the file already meets expectations, where cross-references are missing, and where remediation is needed. This preserves prior work while improving traceability, consistency, and TGA-specific usability within the submission dossier.

Risk management files support Essential Principles compliance by showing how hazards were identified, how risks were reduced, and why residual risks remain acceptable when weighed against benefits. Those conclusions should connect directly to design controls, verification data, labeling warnings, usability considerations, and clinical evidence. When aligned properly, the risk file becomes a core evidence source for demonstrating that the device meets applicable Essential Principles.

It should be done before the ARTG application is submitted, ideally early enough to correct documentation gaps without delaying timelines. Alignment is especially important when adapting files built for FDA, EU MDR, or other markets, because direct reuse often leaves TGA-specific cross-referencing gaps. It is also valuable before major design changes, remediation efforts, or re-engagement after regulatory questions.

Common gaps include outdated hazard analyses after design changes, weak traceability between risks and verification evidence, missing links to labeling or IFUs, incomplete residual risk justifications, and poor integration with clinical or post-market data. Another frequent issue is using a technically compliant ISO 14971 file that is not structured or cross-referenced in a way that supports TGA review expectations within the ARTG submission.